Phaseline

Targets › TXNRD1

TXNRD1 (Thioredoxin reductase 1, cytoplasmic): drug programs, companies and trials

8 programs from 8 companies in 9 trials: 6 Phase 2, 2 Phase 1, 1 Phase 3; Oncology, Hematology, Other; next expected readout Feb 2027.

Reduces disulfide protein thioredoxin (Trx) to its dithiol-containing form. Homodimeric flavoprotein involved in the regulation of cellular redox reactions, growth and differentiation. (UniProt, Q16881)

Open in Phaseline: the race on TXNRD1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Children's Oncology GroupArsenic Trioxide
Thioredoxin reductase 1 inhibitor
TXNRD1Phase 3Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARAJun 2029
The University of Hong KongArsenic Trioxide
Thioredoxin reductase 1 inhibitor
TXNRD1Phase 2Acute Myeloid LeukemiaFeb 2027
Associazione Italiana Ematologia Oncologia PediatricaArsenic Trioxide
Thioredoxin reductase 1 inhibitor
TXNRD1Phase 2Acute Promyelocytic LeukemiaOct 2027
M.D. Anderson Cancer CenterArsenic Trioxide
Thioredoxin reductase 1 inhibitor
TXNRD1Phase 2Acute Promyelocytic Leukemia With PML-RARADec 2027
Yang LiArsenic Trioxide
Thioredoxin reductase 1 inhibitor
TXNRD1Phase 2Neuroblastoma; Pediatric CancerDec 2028
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityArsenic trioxide
Thioredoxin reductase 1 inhibitor
TXNRD1Phase 2NeuroblastomaMay 2031
Groupe Francophone des MyelodysplasiesArsenic Trioxide
Thioredoxin reductase 1 inhibitor
TXNRD1Phase 1Low-risk Myelodysplastic SyndromesJul 2027
Xing XieArsenic trioxide
Thioredoxin reductase 1 inhibitor
TXNRD1Phase 1Efficacy and Safety–

Conditions

Neuroblastoma (2) Pediatric Cancer (1) Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA (1) Acute Promyelocytic Leukemia With PML-RARA (1) Acute Myeloid Leukemia (1) Low-risk Myelodysplastic Syndromes (1) Acute Promyelocytic Leukemia (1) Efficacy and Safety (1)

Modalities

small molecule (6), mixed (2)

Companies

Yang Li (1) Children's Oncology Group (1) M.D. Anderson Cancer Center (1) The University of Hong Kong (1) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) Groupe Francophone des Myelodysplasies (1) Associazione Italiana Ematologia Oncologia Pediatrica (1) Xing Xie (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.